FOXO4-DRI vs Humanin
Updated 9 sources
Key differences
- 1Humanin blocks cell death; FOXO4-DRI triggers it in senescent cells.
- 2Humanin is made by the body and measured in human blood. FOXO4-DRI is fully synthetic, built from D-amino acids.
- 3Opposite jobs: humanin helps stressed cells survive, FOXO4-DRI makes senescent cells die.
- 4Humanin is made by the body and measured in human blood. FOXO4-DRI is a synthetic D-amino acid peptide.
Side by side
Facts from each record, in the same words as their own pages.
| FOXO4-DRI | Humanin | |
|---|---|---|
| Category |
|
|
| Evidence |
|
|
| FDA status |
|
|
| WADA |
|
|
| Half-life |
|
|
| Routes |
|
|
| Forms |
|
|
| Reported doses |
|
|
| Most cited frequency |
|
|
| Vial sizes |
|
|
| Mixed vial keeps |
|
|
| Protocols on file |
|
|
Doses shown are what sources report, labelled by origin. Not medical advice.
Read each in full
Sources
9 sources, each checked by date. Record updated Oct 24, 2026. Numbers are restated in our own words and labelled by where they came from.
Clinical study4
- Hashimoto Y et al. 2001, Mechanisms of neuroprotection by a novel rescue factor humanin, Biochem Biophys Res CommunPubMed · checked Oct 24, 2026
- Baar MP et al. 2017, Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging, CellPubMed · checked Oct 24, 2026
- Yen K et al. 2020, full textPubMed Central · checked Oct 24, 2026
- Chin YP et al. 2013, Pharmacokinetics and tissue distribution of humanin and its analogues in male rodents, EndocrinologyPubMed · checked Oct 24, 2026
Regulatory2
- Bulk drug substances nominated for use in compounding under section 503A (interim categories 1 to 3)FDA · checked Oct 24, 2026
- Certain bulk drug substances for use in compounding that may present significant safety risksFDA · checked Oct 24, 2026
Competitor guide3
- FOXO4-DRIpeptiq.io · checked Oct 24, 2026
- FOXO4-DRI quick start protocolpeptidedosingprotocols.com · checked Oct 24, 2026
- Humaninpeptiq.io · checked Oct 24, 2026